MedTrace Logo

Safety, Tolerability and Clinical Activity of ASM-024 in Stable Moderate Asthma

NCT01190826 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2012-03-15

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability and clinical activity of ASM-024 in stable moderate asthma.

Conditions

Interventions

DRUG

ASM-024

Target dose of 10 mg ASM-024 administered once by inhalation

DRUG

ASM-024 100 mg

Target dose of 100 mg ASM-024 administered once by inhalation

DRUG

Placebo

Placebo administered once by inhalation

Sponsors & Collaborators

  • Asmacure Ltée

    lead INDUSTRY

Principal Investigators

  • Richard Larouche, B. Pharm. MD · Anapharm

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2011-12-31
Completion
2012-02-29

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01190826 on ClinicalTrials.gov